tiprankstipranks
Trending News
More News >
Capstone Therapeutics Corp (CAPS)
NASDAQ:CAPS
US Market

Capstone Therapeutics (CAPS) AI Stock Analysis

Compare
49 Followers

Top Page

CAPS

Capstone Therapeutics

(NASDAQ:CAPS)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
$0.69
▼(-2.25% Downside)
Capstone Therapeutics' overall stock score reflects significant financial challenges, including declining revenue and negative equity, which weigh heavily on the score. While technical indicators are bearish, recent corporate events provide a positive outlook with strategic acquisitions and growth plans. However, the negative valuation metrics further dampen the overall score.
Positive Factors
Strategic Acquisitions
The acquisition of Canadian Stone Industries enhances Capstone's market position and revenue potential, supporting its $100 million revenue target.
Revenue Growth Strategy
Capstone's strategy to achieve $100 million in revenue by 2026 through organic growth and acquisitions indicates a focus on sustainable expansion.
Cash Flow Improvement
Improved cash flow management enhances financial flexibility, allowing Capstone to invest in growth initiatives and manage debt effectively.
Negative Factors
Declining Revenue
The decline in revenue over recent years highlights challenges in market competitiveness and product adoption, impacting long-term growth.
Negative Equity
Negative equity indicates financial instability, limiting Capstone's ability to secure financing and invest in growth opportunities.
Shrinking Profit Margins
Decreasing profit margins suggest cost pressures or pricing challenges, which could hinder profitability and competitive positioning.

Capstone Therapeutics (CAPS) vs. SPDR S&P 500 ETF (SPY)

Capstone Therapeutics Business Overview & Revenue Model

Company DescriptionCapstone Therapeutics (CAPS) is a biotechnology company focused on developing innovative therapies for serious medical conditions. The company operates primarily in the healthcare sector, specializing in the research and development of biologics and pharmaceuticals aimed at treating diseases with significant unmet medical needs. Capstone's core products include advanced therapeutic candidates designed to enhance patient outcomes and improve the quality of life in various therapeutic areas, such as oncology and autoimmune disorders.
How the Company Makes MoneyCapstone Therapeutics generates revenue through multiple streams, primarily from the development and commercialization of its therapeutic products. The company may receive funding from strategic partnerships with larger pharmaceutical companies, including milestone payments and royalties based on product sales once they reach the market. Additional revenue may come from government grants or research contracts that support the development of its therapies. Moreover, licensing agreements for its proprietary technologies can also contribute to its earnings, offering Capstone a diversified revenue model that leverages both product sales and collaborative research efforts.

Capstone Therapeutics Financial Statement Overview

Summary
Capstone Therapeutics faces significant financial challenges, with declining revenue and profitability, alongside negative equity and high leverage, posing substantial risks. While cash flow management shows improvement, the company must address its structural financial weaknesses to restore stability and growth potential.
Income Statement
45
Neutral
Capstone Therapeutics has experienced declining revenue over the past few years, dropping from $61.56M in 2022 to $44.88M in 2024. Gross profit margin decreased from 26.9% in 2022 to 21.3% in 2024, indicating shrinking profitability. The company has posted net losses over the last two years, with a net loss margin of -12.2% in 2024, reflecting ongoing challenges in achieving profitability.
Balance Sheet
30
Negative
The company's balance sheet shows negative stockholders' equity of -$3.06M in 2024, a concerning sign of financial instability and potential risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, further indicating financial distress. These factors suggest significant leverage and financial risk.
Cash Flow
55
Neutral
Capstone has shown improvement in free cash flow from $1.24M in 2023 to $3.70M in 2024, showcasing strong free cash flow growth. The operating cash flow to net income ratio is favorable, though the company continues to face net losses. This implies effective cash management but highlights the need for sustained profitability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue44.72M44.88M48.35M61.56M66.74M45.45M
Gross Profit9.78M9.57M9.61M16.53M16.32M10.94M
EBITDA-2.86M-121.00K-1.75M4.23M5.02M2.64M
Net Income-5.54M-2.56M-3.82M2.31M3.92M10.46M
Balance Sheet
Total Assets58.48M47.22M52.70M65.21M60.85M54.87M
Cash, Cash Equivalents and Short-Term Investments730.00K11.00K52.00K23.00K50.00K0.00
Total Debt23.25M16.61M20.33M28.80M28.34M20.81M
Total Liabilities31.33M50.28M50.26M57.04M31.78M25.77M
Stockholders Equity27.16M-3.06M2.44M8.17M29.08M29.11M
Cash Flow
Free Cash Flow-1.17M3.70M1.24M-3.06M2.55M639.00K
Operating Cash Flow-1.15M3.82M1.45M-2.89M3.72M642.00K
Investing Cash Flow-2.46M-120.00K-208.00K-173.00K-931.00K-3.00K
Financing Cash Flow4.32M-3.74M-1.21M3.04M-2.74M-697.00K

Capstone Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.71
Price Trends
50DMA
0.96
Negative
100DMA
1.12
Negative
200DMA
1.56
Negative
Market Momentum
MACD
-0.05
Positive
RSI
40.43
Neutral
STOCH
16.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPS, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.96, and below the 200-day MA of 1.56, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.43 is Neutral, neither overbought nor oversold. The STOCH value of 16.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPS.

Capstone Therapeutics Risk Analysis

Capstone Therapeutics disclosed 18 risk factors in its most recent earnings report. Capstone Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Capstone Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
46
Neutral
$6.29M-0.09-20.23%1.52%77.22%
41
Neutral
$6.06M-0.03
35
Underperform
$80.13M-0.53-94.35%80.73%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CAPS
Capstone Therapeutics
0.76
-1.48
-66.07%
RETO
ReTo Eco-Solutions
2.12
-43.38
-95.34%
FEAM
5E Advanced Materials, Inc.
3.57
-6.58
-64.83%
STAI
ScanTech AI Systems
3.20
-124.00
-97.48%

Capstone Therapeutics Corporate Events

M&A TransactionsBusiness Operations and Strategy
Capstone Therapeutics Outlines 2026 Growth Strategy
Positive
Dec 15, 2025

On December 15, 2025, Capstone Holding Corp. released an investor presentation detailing its 2026 strategy, emphasizing its growth through acquisitions and organic expansion. The company has successfully integrated recent acquisitions, achieving a $70 million revenue run rate, and is on track to meet its $100 million target by 2026. This strategy positions Capstone to capitalize on deferred construction demand, enhancing its market presence and shareholder value.

M&A TransactionsBusiness Operations and Strategy
Capstone Completes Acquisition of Canadian Stone Industries
Positive
Dec 2, 2025

On December 1, 2025, Capstone Holding Corp. completed the acquisition of Canadian Stone Industries, a distributor with $15 million in annual revenue, which expands Capstone’s North American footprint and strengthens its brand portfolio. This acquisition is expected to immediately increase revenue and EBITDA, advancing Capstone towards its $100 million revenue target for early 2026, and reflects the company’s strategy of acquiring high-quality businesses to enhance its market position.

Private Placements and FinancingBusiness Operations and Strategy
Capstone Therapeutics Adjusts Convertible Note Conversion Price
Neutral
Nov 28, 2025

Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On November 28, 2025, the company and the buyer agreed to reduce the conversion price of the July 2025 Convertible Note to $0.75 for the remaining principal amount of $500,744.01, and for $1,772,856.21 of the October 2025 Convertible Note, potentially impacting the company’s stock conversion strategy.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Capstone Therapeutics Approves Reincorporation to Nevada
Neutral
Nov 24, 2025

On November 18, 2025, Capstone Holding Corp. held its annual stockholders meeting where several key proposals were voted upon. The meeting, which had a quorum with 74.78% of votes represented, resulted in the election of two directors, the ratification of GBQ Partners LLC as the independent auditor, and the approval of the company’s reincorporation from Delaware to Nevada. Additionally, the 2025 Stock Incentive Plan was adopted, and executive compensation was approved to be reviewed every three years. These decisions are likely to impact the company’s governance and operational structure moving forward.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Capstone Therapeutics Reports Record Q3 2025 Financial Results
Positive
Nov 17, 2025

Capstone Holding Corp. reported record financial results for the third quarter of 2025, with a 19% year-over-year increase in pro forma revenue and a 46% rise in adjusted EBITDA. The company announced two acquisitions expected to contribute $26 million in annualized revenue, accelerating its path toward a $100 million run-rate by early 2026. The improved economic conditions and a favorable industry outlook, supported by interest rate cuts and a recovery in demand, provide strong long-term growth prospects for Capstone. The company has also achieved integration milestones with its recent acquisition, positioning itself for rapid post-close integration of future acquisitions.

M&A TransactionsBusiness Operations and Strategy
Capstone Completes Acquisition of Carolina Stone Holdings
Positive
Nov 7, 2025

On August 22, 2025, Capstone Holding Corp. completed its acquisition of Carolina Stone Holdings, LLC, and its subsidiary, Carolina Stone Distributors, LLC, from D22L, Inc. and other sellers. The transaction involved a cash payment of $2,625,000, subject to adjustments, and a seller note of $1,250,000. This acquisition is expected to enhance Capstone’s market presence in the stone products industry by expanding its operational capabilities and market reach.

Private Placements and FinancingRegulatory Filings and Compliance
Capstone Therapeutics Issues Second Convertible Note
Neutral
Oct 23, 2025

Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes. On October 22, 2025, Capstone issued a second convertible note worth $3,545,712.42, convertible into common stock at a price of $1.10 per share. The company received gross proceeds of $3,250,000 from this issuance and plans to file a registration statement with the SEC for the resale of the stock. Joseph Gunnar & Co., LLC acted as the sales agent for this financing.

Private Placements and FinancingBusiness Operations and Strategy
Capstone Therapeutics Strengthens Balance Sheet with Debt Exchange
Positive
Oct 6, 2025

On September 30, 2025, Capstone Holding Corp. entered into an Exchange Agreement with Brookstone entities to exchange $1.9 million in debt for newly issued non-convertible preferred equity, Series Z Preferred shares. This strategic move, approved by the Board, strengthens Capstone’s balance sheet by eliminating targeted debt and reducing interest expenses by over $170,000, without diluting common shareholders. The transaction enhances Capstone’s financial flexibility, positioning the company for potential accretive acquisitions and signaling confidence in its long-term cash flows.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 19, 2025